ZPDH:F:F-SPDR S&P U.S. Health Care Select Sector UCITS (EUR)

ETF | Others |

Last Closing

USD 40.12

Change

+0.03 (+0.06)%

Market Cap

USD 0.40B

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-07-05 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
PRAJ:F Amundi Index Solutions - Amund..

+0.50 (+1.85%)

USD 139.20B
UIM5:F UBS (Lux) Fund Solutions - MSC..

+0.88 (+1.73%)

USD 115.53B
SXR8:F iShares Core S&P 500 UCITS ETF..

+5.96 (+1.09%)

USD 96.59B
ZPDJ:F SPDR® MSCI Japan UCITS ETF

+0.98 (+1.78%)

USD 94.63B
SXRZ:F iShares VII PLC - iShares Nikk..

+4.25 (+1.78%)

USD 57.94B
XDNY:F Xtrackers MSCI Japan ESG Scree..

N/A

USD 54.05B
VUAA:F Vanguard S&P 500 UCITS Acc

+1.41 (+1.45%)

USD 51.63B
VUSA:F Vanguard Funds Public Limited ..

+1.21 (+1.24%)

USD 51.63B
XJSE:F Xtrackers II - Japan Governmen..

-0.09 (-1.11%)

USD 40.74B
0ZC:F Zscaler Inc

+0.20 (+0.13%)

USD 37.92B

ETFs Containing ZPDH:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 8.64% 60% D- 65% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 8.64% 56% F 57% F
Trailing 12 Months  
Capital Gain 11.15% 55% F 63% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 11.15% 53% F 55% F
Trailing 5 Years  
Capital Gain 70.43% 86% B+ 78% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 70.43% 86% B+ 66% D+
Average Annual (5 Year Horizon)  
Capital Gain 12.05% 84% B 76% C+
Dividend Return 12.05% 82% B 70% C-
Total Return N/A 72% C 96% N/A
Risk Return Profile  
Volatility (Standard Deviation) 10.89% 60% D- 84% B
Risk Adjusted Return 110.70% 99% N/A 98% N/A
Market Capitalization 0.40B 55% F 46% F

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike